Adjusted HRs for AMI or CHD death and 95% CIs for time-updated mean HbA1c categories together with albuminuria and eGFR versus the reference group examined by Cox regression
| AMI or CHD death | HR (95% CI) P value | ||
| Model 3 All patients and controls | Model 3a Male patients and controls | Model 3b Female patients and controls | |
| Time-updated mean HbA1c categories albuminuria and eGFR | Events (n)=136 231 Subjects (n)=2 445 866 | Events (n)=84 382 Subjects (n)=1 323 072 | Events (n)=51 849 Subjects (n)=1 122 794 |
| Controls (reference) | 1.00 | 1.00 | 1.00 |
| ≤6.9% (≤52 mmol/mol):normoalbuminuria and eGFR ≥60 | 0.95 (0.92 to 0.98) 0.0009 | 0.94 (0.90 to 0.98) 0.0014 | 0.98 (0.93 to 1.04) 0.56 |
| 7.0%–7.8% (53–62 mmol/mol):normoalbuminuria and eGFR ≥60 | 1.21 (1.16 to 1.25) <0.0001 | 1.16 (1.11 to 1.22) <0.0001 | 1.31 (1.23 to 1.40) <0.0001 |
| 7.9%–8.7% (63–72 mmol/mol):normoalbuminuria and eGFR ≥60 | 1.63 (1.54 to 1.72) <0.0001 | 1.51 (1.41 to 1.62) <0.0001 | 1.87 (1.71 to 2.04) <0.0001 |
| 8.8%–9.6% (73–82 mmol/mol): normoalbuminuria and eGFR ≥60 | 1.92 (1.75 to 2.10) <0.0001 | 1.75 (1.56 to 1.96) <0.0001 | 2.25 (1.94 to 2.60) <0.0001 |
| ≥9.7% (≥83 mmol/mol):normoalbuminuria and eGFR ≥60 | 2.73 (2.42 to 3.09) <0.0001 | 2.51 (2.16 to 2.93) <0.0001 | 3.09 (2.53 to 3.78) <0.0001 |
| ≤6.9% (≤52 mmol/mol):not normoalbuminuria or eGFR <60 | 1.40 (1.37 to 1.44) <0.0001 | 1.39 (1.34 to 1.43) <0.0001 | 1.42 (1.36 to 1.47) <0.0001 |
| 7.0%–7.8% (53–62 mmol/mol):not normoalbuminuria or eGFR <60 | 1.70 (1.65 to 1.75) <0.0001 | 1.65 (1.58 to 1.71) <0.0001 | 1.78 (1.69 to 1.86) <0.0001 |
| 7.9%–8.7% (63–72 mmol/mol):not normoalbuminuria or eGFR <60 | 2.11 (2.03 to 2.20) <0.0001 | 2.04 (1.94 to 2.15) <0.0001 | 2.21 (2.07 to 2.35) <0.0001 |
| 8.8%–9.6% (73–82 mmol/mol):not normoalbuminuria or eGFR <60 | 2.48 (2.33 to 2.63) <0.0001 | 2.41 (2.23 to 2.60) <0.0001 | 2.56 (2.33 to 2.81) <0.0001 |
| ≥9.7% (≥83 mmol/mol): not normoalbuminuria or eGFR <60 | 2.94 (2.71 to 3.19) <0.0001 | 2.77 (2.49 to 3.09) <0.0001 | 3.14 (2.77 to 3.56) <0.0001 |
Adjusted for time-updated age and sex (for all patient models), time-updated diabetes duration (centred at median 8 years), born in Sweden, maximum education level and baseline comorbidities (AF, CHD, HF, VD, stroke, cancer).
AF, atrial fibrillation; AMI, acute myocardial infarction; CHD, coronary heart disease; HF, heart failure; VD, valve disease; eGFR, estimated glomerular filtration rate.